|
|
Article: Aldagen and Texas Heart Institute to Begin Clinical Study of Stem Cell Therapy for Advanced Heart Failure Patients; FDA Clears IND to Begin Clinical Study.
- Article from:
- Business Wire
- Article date:
- February 21, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DURHAM, N.C. -- Aldagen, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared a clinical study for physicians led by Dr. Emerson Perin and Dr. James Willerson of the Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, Texas, to conduct a clinical trial using Aldagen's ALDESORT product to isolate a unique stem cell population for therapy for advanced heart failure patients. It will be the first clinical trial involving this unique cell population for therapy for heart failure patients in the United States.
"We are very excited about the FDA clearance to begin this work in the Texas Medical Center at the Texas Heart ...